Evidence map›Paper›PMID 42043271›Full record

ArticleViruses2026

Next-Generation Sequencing Strategies During the 2024-2025 Avian Influenza A(H5N1) Emergency Response in the U.S.

Julia C Frederick, Kristine A Lacek, Matthew J Wersebe, Bo Shu, Lisa M Keong, Juliana DaSilva, Malania M Wilson, Sydney R Sheffield, Jimma Liddell, Natasha Burnett and 18 more

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Julia C FrederickInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Kristine A LacekInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0002-6247-5082
Matthew J WersebeInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0001-9973-6410
Bo ShuInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Lisa M KeongInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0001-8211-659X
Juliana DaSilvaInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Malania M WilsonInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-3486-1725
Sydney R SheffieldInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0002-7481-1207
Jimma LiddellInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0009-0007-0226-5183
Natasha BurnettInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Reina ChauInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-3012-1404
Amanda H SullivanInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-2007-4210
Yunho JangInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Juan A De La CruzInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0002-0712-065X
Elizabeth A PuschInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0001-8193-710X
Dan CuiInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Yasuko HattaInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Sabrina SchatzmanInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Norman HassellInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Xiao-Yu ZhengInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-4285-5579
Ha T NguyenInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Larisa GubarevaInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Rebecca KondorInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Han DiInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Vivien G DuganInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Charles T DavisInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Benjamin L Rambo-MartinInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0002-8591-3954
Marie K KirbyInfluenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-0859-9604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first influenza A(H5N1) human case associated with the A(H5N1) dairy cattle outbreak in the United States was identified in April 2024. The U.S. CDC response to this outbreak was activated days later and remained active until July 2025. During this time, 70 human cases of influenza A(H5N1) were detected with a range of epidemiological links to sources of exposure. Next-generation sequencing (NGS) of human samples was an effectual mechanism for tracking and analyzing the outbreak evolution throughout the response. Due to the specimens' importance and their variable physical quality, an assortment of laboratory methods was utilized including influenza segment-specific amplification, enrichment capture, short-read, and long-read sequencing. Combining these methods allowed for high-quality genomic data production with rapid turnaround times-typically 2 days from sample receipt to public database submission. By leveraging replicate sequencing, enrichment capture, and sequencing of diagnostic amplicons, valuable genomic data could be produced directly from human clinical specimens that would have normally been considered too weak for routine virologic surveillance sequencing. The resulting assemblies were characterized and analyzed by CDC and shared with local and state public health authorities to facilitate case investigations and risk assessment. These data were further used for phylogenetic analyses of viruses from human cases to investigate likely animal-to-human transmission events and identify clusters within the outbreak that might indicate trends in the types of exposures. Through the adaptable laboratory workflow and the rapid release of viral genomic data, the public health risk mitigation strategies could be evaluated and adjusted in real time.

Indexed as

High-Throughput Nucleotide SequencingInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInfluenza in BirdsAnimalsCattleCattle DiseasesDisease OutbreaksGenome, ViralHumansPhylogenyUnited Statesavian influenzaH5N1next-generation sequencingpublic healthresponse structure

Identifiers

PMID42043271
PMCPMC13120661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.